Trials / Suspended
SuspendedNCT04485052
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Demethylating Agents in Subjects With Acute Myeloid Leukemia
- Status
- Suspended
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 222 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is to evaluate safety, tolerability and composite CR of IBI188 plus Demethylating Agents in acute myeloid leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI188 | anti-CD47 Monoclonal antibody |
| DRUG | Azacitidine | Demethylation drugs |
| DRUG | Decitabine | Demethylation drugs |
Timeline
- Start date
- 2020-09-25
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
- First posted
- 2020-07-24
- Last updated
- 2023-10-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04485052. Inclusion in this directory is not an endorsement.